Mining the full potential of GPCR signaling to innovate novel drugs.


Conformation Driven Drug Discovery for GPCRs


Our proprietary membrane protein-NMR drug discovery platform identifies highly signaling-pathway selective molecules that bind to G-protein coupled receptor (GPCR) targets, eliminating on-target adverse effects that limit therapeutic index.


Our Progress


We know the value of innovative drug discovery and development…

MEBIAS’ business model is comprised of partnering and advancing its own molecules into early clinical development. Six years since its founding, the company has validated its unique drug discovery, identified a novel preclinical mu-opioid candidate entering Phase 1 human clinical studies in 2022, and currently developing Sphingosine 1-phosphate receptor (S1PR1) agonists for the treatment of neuropathic pain.


3675 Market Street Suite 200

Philadelphia, PA 19104

Call Us